Free Trial
→ Trump to redistribute trillions of dollars (From Porter & Company) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • Interested in Denali Therapeutics? Here are five stocks we like better.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover
The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
3.8422 of 5 stars		$14.39-0.3%N/A-5.21Buy$33.79
Ultragenyx Pharmaceutical (RARE)
4.3238 of 5 stars		$35.16-2.3%N/A-5.55Moderate Buy$90.93
Sarepta Therapeutics (SRPT)
4.7226 of 5 stars		$36.27-0.7%N/A29.02Moderate Buy$131.22
Pfizer (PFE)
4.9993 of 5 stars		$22.28-3.0%7.72%15.80Moderate Buy$29.17
Exelixis (EXEL)
4.1651 of 5 stars		$36.17-0.9%N/A20.44Hold$37.59
Moderna (MRNA)
4.4035 of 5 stars		$24.25-0.5%N/A-2.61Hold$53.95
United Therapeutics (UTHR)
4.9852 of 5 stars		$301.42-2.1%N/A13.24Moderate Buy$392.00
Biogen (BIIB)
4.7536 of 5 stars		$118.20-0.2%N/A10.56Hold$191.30
Sanofi (SNY)
4.3272 of 5 stars		$49.98-4.1%3.20%20.07Buy$63.33
Eli Lilly and Company (LLY)
4.9948 of 5 stars		$736.21-2.0%0.81%62.87Moderate Buy$1,002.80
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines